Intriguingly, the first‐in‐class PTPN2/N1 inhibitor AC484 shows a great anti‐tumor effect against ALK+ ALCL, providing a rationale for conducting clinical trials of AC484 on ALK+ ALCL patients (Figure 7J). This evidence concerns the gene ALK and anaplastic large cell lymphoma.